Table 1.
Patient characteristics in the three largest anti-CD19 multicenter studies CAR T-cells in aggressive B-cell NHLs.
| Patients Characteristics | ZUMA-1 (Neelapu, 2017) | JULIET (Schuster, 2017) | TRANSCEND (Abramson, 2017) |
|---|---|---|---|
| No of patients enrolled | 111 (101) | 141 (85) | 91 (67) |
| Median age, range | 58 (23–76) | 56 (24–75) | 61 (29–82) |
| Age ≥ 65 | 24% | 21% | 17% |
| Lymphoma subtypes | DLBCL, TFL, PMBCL | DLBCL, TFL | DLBCL, TFL (CORE)a |
| Double hit lymphomas | NR | 27% | 27% |
| ≥ 3 lines of therapy | 69% | 50% | 50% |
| Primary refractoriness | 26% | NR | NR |
| Refractory to > 2nd line | 77% | NR | 76% |
| Relapse post ASCT | 21% | 51% | 44% |
DLBCL: Diffuse Large B-cell Lymphoma, TFL: Transformed lymphoma, FL: Follicular lymphoma, ASCT: Autologous Stem Cell Transplantation, NR: Not Reported.
a
The FULL cohort included: DLBCL transformed from CLL (Richter transformation) and marginal zone lymphoma (MZL), PMBCL and follicular lymphoma 3B